跳至主要内容
临床试验/CTRI/2007/091/000042
CTRI/2007/091/000042已完成2 期

Safety and efficacy comparison of two NN1250 formulations and insulin glargine all in combination with metformin in insulin naive subjects with type 2 diabetes, measured by HbA1c after 16 weeks of treatment

ovo Nordisk AS0 个研究点目标入组 116 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
116

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Insulin naive type 2 subjects for at least 3 months
  • 2. Treatment with a stable dosing of maximally tolerated dose or at least half maximally allowed dose of one or two OADs for at least 2 months
  • 3. HbA1c 7.0-11.0% (both inclusive)
  • 4. Body mass index (BMI) 25-42 kg/m2 (both inclusive)

排除标准

  • 1. Metformin contraindication according to local practice
  • 2. Treatment with thiazolidinedione (TZD) within the last 3 months prior to screening
  • 3. Any systemic treatment with products which in the investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) 3 months prior to randomisation
  • 4. Any disease or condition which according to the investigator would interfere with the trial

研究者

发起方
ovo Nordisk AS

相似试验